Related Experiment Videos

Use of a beta-agonist in ventilated, very-low-birth-weight babies: a longitudinal evaluation

S J Kovacs1, J B Fisher, N L Brodsky

  • 1Division of Neonatology, Albert Einstein Medical Center, Philadelphia, Pa.

Developmental Pharmacology and Therapeutics
|January 1, 1990
PubMed

Insights

Ventilated preterm infants do not show a specific age for responding to beta-agonists. Individual pulmonary function testing is recommended to identify infants who will benefit from these treatments.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Preterm infants often require mechanical ventilation.
  • The efficacy of beta-agonists in this population is variable.
  • Identifying predictors of response is crucial for optimizing treatment.

Purpose of the Study:

  • To investigate if a specific postnatal age (PNA) or postconceptional age (PCA) correlates with beta-agonist response in ventilated preterm infants.
  • To assess individual variability in response to albuterol.

Main Methods:

  • Evaluated 15 preterm infants (mean GA 26.5 weeks) requiring mechanical ventilation.
  • Performed weekly pulmonary function testing (PFT) before and after albuterol administration.
  • Utilized regression analysis to examine the relationship between PNA/PCA and response.

Main Results:

  • No significant relationship was found between PNA or PCA and beta-agonist response when analyzing the group as a whole.
  • Individual infant analysis revealed consistent responders and non-responders.
  • Albuterol administration did not show a consistent age-dependent effect.

Conclusions:

  • Beta-agonist response in ventilated preterm infants is not age-dependent.
  • Individualized pulmonary function testing (PFT) is essential to identify infants likely to benefit from beta-agonists.
  • Tailoring treatment based on PFT can improve therapeutic outcomes.

Related Concept Videos